A Registered Cohort Study of Immune-Mediated Neuropathies

Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trial

Official title:

A Registered Cohort Study of Immune-Mediated Neuropathies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04292834
• Other study ID #: MRCTA,ECFAH of FMU2019217
• Status: Recruiting
• Start date: February 29, 2020
• Est. completion date: January 19, 2025

Study information

• Verified date: December 2021
• Source: First Affiliated Hospital of Fujian Medical University
• Contact: Lin Yi, PhD
• Phone: 86-0591-87982772
• Email: linyi7811[@]163.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will provide further insights into the natural course of the disease about Immune-Mediated Neuropathies including clinical features，progression, related antibody spectrum and drug treatment effect.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: January 19, 2025
• Est. primary completion date: January 19, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1. Outpatient or inpatient 2. Meet the diagnostic criteria of various inflammatory peripheral neuropathy. 3. Voluntary participation and informed consent signed by the applicant or his/her family.

4. Age 18 or above

Exclusion Criteria:

1. Severe complications

2. Poor prognosis (<1 year survival)

3. Severe mental disorder and inability to cooperate with the examination.

4. Age less than 18

Related Conditions & MeSH terms

• Chronic Inflammatory Demyelinating Polyneuropathy
• Polyneuropathies
• Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Locations

Country	Name	City	State
China	Beijing Tiantan Hospital, Capital Medical University	Beijing	Beijing
China	Department of Neurology,First Affiliated Hospital of Fujian Medical University	Fuzhou	Fujian

Sponsors (2)

Lead Sponsor	Collaborator
First Affiliated Hospital of Fujian Medical University	Beijing Tiantan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The correlation between clinical phenotypes and Serum antibodies	Different clinical subtypes of GBS and CIDP have different course and prognosis.It may be related to different serum antibodies.	from date of enrollment until the date of death from any cause,assessed up to 20 years